HUE025355T2 - Kompozíció pulmonáris hipertensio kezeléséhez - Google Patents
Kompozíció pulmonáris hipertensio kezeléséhez Download PDFInfo
- Publication number
- HUE025355T2 HUE025355T2 HUE07855065A HUE07855065A HUE025355T2 HU E025355 T2 HUE025355 T2 HU E025355T2 HU E07855065 A HUE07855065 A HU E07855065A HU E07855065 A HUE07855065 A HU E07855065A HU E025355 T2 HUE025355 T2 HU E025355T2
- Authority
- HU
- Hungary
- Prior art keywords
- ambrisentan
- subjects
- placebo
- pah
- baseline
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (7)
- SZABADALMI IGÉNYPONTOK1. Roíí's'íOííWíí, y iaataint«;;: sstibdsemant íelbassnalaasa pul-nenavia bipss'iestsix? állapot kesdéxdv alanyban annak ierapiásan batasos n:e;nvyl.segenek adagolása te ed; sx alany szántása, akis a bázis vonalon, az akn-ybd; állapot elO dnsgsibexaeak ídtgétol számított idő sem több, ntln- 2 év és aböl a? andxn.emsn kontbínádbs lesaoiábaa tan adagolva Ibszbxbesstes'áz-á (PDES) bsbíbltoival, amely k; va:n választva stláenaill, taáalatn és vatiieitatíl közül.
- 2, .Az 1. igém pom szei'lnb kompozíok;, öböl az alanynak axtanö a da go la skov. az alany tapasztana & következők legalább egyikét: (aj egy vagy Óbb heuxdinannkai ·χη:κ·χ·ηχ boseátgaebása, asnetyek a polnexenx hipenensio állapot javulását ;m;l:abák a normáikhoz kbedebh: sein; ide a bank; vonalhoz kcgest (bí lesé tebeaitöképességjaviilásáí a báessvoitalbo® képest; (el Bevy dyspeog Index IBDI} esokkeoéseí a: báxov Ondiam képest: (di) egy vagy több éisímivtöség pasamét;·:?' ja válását a bázisvomsShiXZ képest; éstvagy (e) mozgás; a;?x sonyabb WHO binkdboszlálybs, 2. .A.;.· j. vagy 2. ményposn szerinti kösnposvoiö telbimznátásra, aboi se alanynak iöiténö saiagotás niât! a közepes eákbinéik; ayovnás (PAP) legalább5 Hg mm· el csökkent, előnyöseit legalább .5 Hyonmrl. a feázisvonallíos képest. 4. Λ.··: í-s Igénypoítívvk bámtelytke szerinti: kovopozido ielltaszsiálásm, ahol az aJaityaak adéne adagolás alán a mér; lest: teljesítőképesség lavvtfe legalább Itt m-el eibityősert legalább 2(1 in ö pettes jáitbávolaágban íbM WD; ;
- 5. Az 1-4. igénypontok bévsaeh Ike szentsti kompozíció lelhasználasra, ahol a>·. alanynak történő adagolás étén, BDI : sokkévá legalább 0,5 bxlexponttal, e lee Aden legalább 1 index ponttal, a bázisvonalboz képest, ö. As I··::·. tgénypomd; ItámveKske szedné kompozteiő tetlsisznátásra, als4 a bázisvemdost az alany állapotának dsö díagnödsa étán az «bt nets több, iráni 0.5 év.
- 7. Az l-é. igénypontok báoneiyike szerinti kompozíció lelhasználásm, «hol a poimonans lépertenslo állapét tartalmas pábnonads artériás liiperiea:n<a (PAH). b. A ?. méoypo-x szentül kosnpozaáö Izobassnáissra, ahol a FAJI bas 1st tava len legalább WHO II. osztályban van.
- 9, A k, igénypont szedni! kompozlotö mibasználásra, akit as alanynak van a bázlsvonaton s következők közűi legalább egy, előnyösen as basses ; isi közepes PAP: legalább 25 .l!y.n;m ityngalesebas vagy legalább ab Hgnttn lesd igénybevételnél, (b) paknonasls vaseetaids sezisziendn (PVRt legalálát 3 llgnmPl.Wm. ésA'agy (el pdmonzris kapilláris eOaovIás; nyomás (PCWP) vagy bdka:ora végillaszlalés nyonvás (i.A'PDP) nenv nap yobb. iráni 15 iigntnt. U.s. â S. igoovgeas amuk; kswpozsvk klba vassá Ossa, a hei síz eianyssak ;í bázkvosssss közepes oysxgako PAP éneke legalább körulbehl; 40 i -pneu ; I. Λ>·: j-IÖ, igslnypaatefc bármelyike vzssrksd k>r;;posbvih bsshaveMOsra, sshol az ieskrisereae cs a PDlïS inbsböer •••»ráhvass vae astssgolva egyszsa· rísípsvsía. ! 1 As: ML igenypsaosb, bssnvehase szeresd kossaxedess! klbssezssiibbns, aboi se ss-nbosesXssx zaps ; psg - 2 S mg bsksebssv, donyeeea 2.S as;.·: - i b svg sbksabssíi s en ssdagskv«,
- 13. Ae 1Ί2, iaessyprasSek ixevielyske sZssnxb ksxsspozíek hbb;s\zsdii;ksii. sslsel ;s:e sssvbsbvnex; és a PDE5 ssshibkx legsbabb; egy Olssug ko/escsi idikssztasvbass, ebxsyöseo: kg&isbk bárom bóssxpbssrs vas adagéba.
- 14. Ae MB. igsksypossrek bármelyike szobás; kmvpoelcbl se!;sssesaia\ra. aha; a goavoisáiiss alperíessse adages WHO: 20 oaopostokasrs vass Oísszzályozva, 15. A 14, sgéayposx széna·; k;x;xv>zxao klkssersalsbra, aboi ass átlapoz ssszmlmaz balokba; pb vas' vagy Basez selvbosegiségeí éd vagy batsdsMl val vasári:·; seBbaiegsséget lb. A 14 vagy 15. OöaypeaS szénád BxrspozMó IcihsezoaBara. alsói az álkaxss ksspesobkdk egylsez vagy sëbbbôg a köve;kezek közül: kssksrhse zxssüzsküv gabssossan.s beSegsdg CCObOy bkezsboiálB Ibsbibeksgeeg, alvászavarra légzés. Hveelasix blpisysissblàvlèa zavar, nagy asagasságoek sönesso kozokaz káé soi, de Odes: svobelleeessivz. pcozzysssbs és/vagy stHsálb; pubeonsev; anasvsk íbsvmbssesszboSiyrss obsdzskvldia, ssesss sksssssixstlkas pabaosHkP essbxsba. ·<;;:νοΙ·1ο:>;\. bszsmebosis X. lyîriphassgloszsamvb, ez-oagy bldooM·· i-omprsmzzax;·. !?, A:e 10 b. sgévygosssek bkrsveb ik; aeesiski kunspozieib lelhazzsBkivra, ahoi az asx-brOeovu; adssgssllxa egy he ras pars belad eldssyoeva egy hdless bolkl kezsibbik sr-og a ilsagooriz avas;
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US86966706P | 2006-12-12 | 2006-12-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
HUE025355T2 true HUE025355T2 (hu) | 2016-02-29 |
Family
ID=39092031
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HUE07855065A HUE025355T2 (hu) | 2006-12-12 | 2007-12-11 | Kompozíció pulmonáris hipertensio kezeléséhez |
HUS1600027C HUS1600027I1 (hu) | 2006-12-12 | 2016-05-20 | Kompozíció pulmonáris hipertensio kezeléséhez |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HUS1600027C HUS1600027I1 (hu) | 2006-12-12 | 2016-05-20 | Kompozíció pulmonáris hipertensio kezeléséhez |
Country Status (15)
Country | Link |
---|---|
US (7) | US20080139593A1 (hu) |
EP (2) | EP2952193A1 (hu) |
JP (1) | JP2010512414A (hu) |
AU (1) | AU2007333115B2 (hu) |
CA (1) | CA2669536C (hu) |
CY (1) | CY2016017I2 (hu) |
DK (1) | DK2101777T3 (hu) |
ES (1) | ES2544724T3 (hu) |
HK (1) | HK1218393A1 (hu) |
HU (2) | HUE025355T2 (hu) |
LU (1) | LU93081I2 (hu) |
PL (1) | PL2101777T3 (hu) |
PT (1) | PT2101777E (hu) |
SI (1) | SI2101777T1 (hu) |
WO (1) | WO2008073928A1 (hu) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT2101777E (pt) | 2006-12-12 | 2015-09-18 | Gilead Sciences Inc | Composição para tratar uma hipertensão pulmonar |
AU2008275179B2 (en) | 2007-07-11 | 2013-09-12 | Lexicon Pharmaceuticals, Inc. | Methods and compositions for treating pulmonary hypertension and related diseases and disorders |
US8217155B2 (en) * | 2007-07-31 | 2012-07-10 | Gilead Colorado, Inc. | Metabolites and derivatives of ambrisentan |
WO2010062640A1 (en) * | 2008-10-28 | 2010-06-03 | Gilead Colorado, Inc. | Methods for treating idiopathic pulmonary fibrosis and associated complications |
EA201291274A1 (ru) * | 2010-06-30 | 2013-12-30 | Джилид Сайэнс, Инк. | Применение антагонистов аденозиновых рецепторов aдля лечения легочной гипертензии |
SI2637664T1 (sl) * | 2010-10-15 | 2017-07-31 | Gilead Sciences, Inc. | Sestavki in postopki zdravljenja pljučne hipertenzije |
WO2013024022A1 (en) * | 2011-08-12 | 2013-02-21 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for treatment of pulmonary hypertension |
US20130225595A1 (en) * | 2012-02-29 | 2013-08-29 | Gilead Sciences, Inc. | Method for treating pulmonary arterial hypertension in a patient not having idiopathic pulmonary fibrosis |
US20130224306A1 (en) * | 2012-02-29 | 2013-08-29 | Gilead Sciences, Inc. | Method for treating a pulmonary hypertension condition without companion diagnosis |
WO2014003678A1 (en) * | 2012-06-28 | 2014-01-03 | Xspray Microparticles Ab | Pharmaceutical compositions comprising ambrisentan and solid dispersion particles containing tadalafil |
WO2015193889A1 (en) * | 2014-06-18 | 2015-12-23 | Sonivie Ltd. | Method for treating secondary pulmonary hypertension |
US10576083B2 (en) * | 2015-08-13 | 2020-03-03 | Cipla (UK) Limited | Method of treating pulmonary arterial hypertension |
SG11202000893QA (en) * | 2017-08-30 | 2020-02-27 | Bellerophon Pulse Tech Llc | Use of inhaled nitric oxide for the treatment of pulmonary hypertension associated with lung disease |
MX2020006741A (es) * | 2017-12-28 | 2020-11-24 | Bellerophon Pulse Tech Llc | Uso de oxigeno y oxido nitrico inhalado para el tratamiento de la hipertension pulmonar. |
WO2020225297A1 (en) * | 2019-05-06 | 2020-11-12 | Actelion Pharmaceuticals Ltd | Methods for treating sarcoidosis-associated pulmonary hypertension |
EP4076398A4 (en) | 2019-12-16 | 2024-01-03 | Tenax Therapeutics, Inc. | LEVOSIMENDAN TO TREAT PULMONARY HYPERTENSION ACCOMPANIED BY HEART FAILURE BY MEANS OF PRESERVED EJECTION FRACTION (PH-HF-PEF) |
RU2729033C1 (ru) * | 2020-02-03 | 2020-08-03 | Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр кардиологии" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ кардиологии" Минздрава России) | Способ прогнозирования эффективности длительной специфической терапии у пациентов с идиопатической легочной гипертензией и неоперабельной хронической тромбоэмболической легочной гипертензией |
EP4142731A1 (en) * | 2020-04-28 | 2023-03-08 | Noorik Biopharmaceuticals AG | Treatment of pulmonary complications of coronavirus infections |
EP3906928A1 (en) * | 2020-05-06 | 2021-11-10 | Noorik Biopharmaceuticals AG | Treatment of pulmonary complications of coronavirus |
WO2024151502A1 (en) * | 2023-01-09 | 2024-07-18 | Scpharmaceuticals Inc. | Methods of treatment using loop diuretics |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
US4325525A (en) | 1980-11-13 | 1982-04-20 | General Motors Corporation | Mounting member |
US5364620A (en) | 1983-12-22 | 1994-11-15 | Elan Corporation, Plc | Controlled absorption diltiazem formulation for once daily administration |
US4902514A (en) | 1988-07-21 | 1990-02-20 | Alza Corporation | Dosage form for administering nilvadipine for treating cardiovascular symptoms |
US5250534A (en) | 1990-06-20 | 1993-10-05 | Pfizer Inc. | Pyrazolopyrimidinone antianginal agents |
DE4313412A1 (de) | 1993-04-23 | 1994-10-27 | Basf Ag | 3-(Het)aryl-Carbonsäurederivate, Verfahren und Zwischenprodukte zu ihrer Herstellung |
GB9401090D0 (en) | 1994-01-21 | 1994-03-16 | Glaxo Lab Sa | Chemical compounds |
DE19533023B4 (de) | 1994-10-14 | 2007-05-16 | Basf Ag | Neue Carbonsäurederivate, ihre Herstellung und Verwendung |
CU23063A3 (es) | 1997-11-12 | 2005-07-19 | Bayer Ag | Imidazotriazinonas 2-fenil sustituidas como inhibidores de fosfodiesterasas |
US6821975B1 (en) | 1999-08-03 | 2004-11-23 | Lilly Icos Llc | Beta-carboline drug products |
WO2006007213A1 (en) * | 2004-06-23 | 2006-01-19 | Myogen, Inc. | Enoximone formulations and their use in the treatment of pde-iii mediated diseases |
US20060205733A1 (en) | 2004-08-26 | 2006-09-14 | Encysive Pharmaceuticals | Endothelin a receptor antagonists in combination with phosphodiesterase 5 inhibitors and uses thereof |
CN101072564A (zh) | 2004-08-26 | 2007-11-14 | 恩希赛弗制药公司 | 内皮缩血管肽a受体(eta)拮抗剂与磷酸二酯酶5(pde5)抑制剂的联合及其用途 |
EP1846411A4 (en) | 2005-01-25 | 2010-08-04 | Glaxo Group Ltd | ANTIBACTERIAL ACTIVE SUBSTANCES |
WO2007122466A1 (en) * | 2006-04-21 | 2007-11-01 | Pfizer Products Inc. | Pyridine[3,4-b]pyrazinones |
EP2091539A1 (en) * | 2006-12-12 | 2009-08-26 | Gilead Colorado, Inc. | Ambrisentan combined with a renin inhibitor for hypertensive disorder |
PT2101777E (pt) | 2006-12-12 | 2015-09-18 | Gilead Sciences Inc | Composição para tratar uma hipertensão pulmonar |
US8217155B2 (en) | 2007-07-31 | 2012-07-10 | Gilead Colorado, Inc. | Metabolites and derivatives of ambrisentan |
WO2010062640A1 (en) | 2008-10-28 | 2010-06-03 | Gilead Colorado, Inc. | Methods for treating idiopathic pulmonary fibrosis and associated complications |
SI2637664T1 (sl) | 2010-10-15 | 2017-07-31 | Gilead Sciences, Inc. | Sestavki in postopki zdravljenja pljučne hipertenzije |
-
2007
- 2007-12-11 PT PT78550654T patent/PT2101777E/pt unknown
- 2007-12-11 US US11/953,955 patent/US20080139593A1/en not_active Abandoned
- 2007-12-11 PL PL07855065T patent/PL2101777T3/pl unknown
- 2007-12-11 EP EP15168201.0A patent/EP2952193A1/en not_active Withdrawn
- 2007-12-11 WO PCT/US2007/087058 patent/WO2008073928A1/en active Application Filing
- 2007-12-11 EP EP07855065.4A patent/EP2101777B1/en not_active Revoked
- 2007-12-11 HU HUE07855065A patent/HUE025355T2/hu unknown
- 2007-12-11 DK DK07855065.4T patent/DK2101777T3/en active
- 2007-12-11 CA CA2669536A patent/CA2669536C/en active Active
- 2007-12-11 SI SI200731668T patent/SI2101777T1/sl unknown
- 2007-12-11 AU AU2007333115A patent/AU2007333115B2/en active Active
- 2007-12-11 JP JP2009541511A patent/JP2010512414A/ja not_active Withdrawn
- 2007-12-11 ES ES07855065.4T patent/ES2544724T3/es active Active
-
2010
- 2010-02-17 US US12/706,818 patent/US20100152217A1/en not_active Abandoned
-
2011
- 2011-06-16 US US13/162,137 patent/US8377933B2/en active Active
-
2012
- 2012-12-21 US US13/723,758 patent/US20130116257A1/en not_active Abandoned
-
2014
- 2014-02-17 US US14/182,208 patent/US9474752B2/en active Active
-
2015
- 2015-04-24 US US14/695,775 patent/US9504685B2/en active Active
-
2016
- 2016-05-20 CY CY2016017C patent/CY2016017I2/el unknown
- 2016-05-20 LU LU93081C patent/LU93081I2/fr unknown
- 2016-05-20 HU HUS1600027C patent/HUS1600027I1/hu unknown
- 2016-06-06 HK HK16106422.7A patent/HK1218393A1/zh unknown
- 2016-11-23 US US15/360,304 patent/US9993475B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
US9993475B2 (en) | 2018-06-12 |
CA2669536A1 (en) | 2008-06-19 |
US20150224100A1 (en) | 2015-08-13 |
DK2101777T3 (en) | 2015-08-17 |
HUS1600027I1 (hu) | 2016-06-28 |
US9474752B2 (en) | 2016-10-25 |
WO2008073928A1 (en) | 2008-06-19 |
US8377933B2 (en) | 2013-02-19 |
EP2101777A1 (en) | 2009-09-23 |
LU93081I2 (fr) | 2016-07-20 |
SI2101777T1 (sl) | 2015-08-31 |
ES2544724T3 (es) | 2015-09-03 |
EP2952193A1 (en) | 2015-12-09 |
CY2016017I1 (el) | 2016-10-05 |
US20100152217A1 (en) | 2010-06-17 |
CY2016017I2 (el) | 2016-10-05 |
US20130116257A1 (en) | 2013-05-09 |
US20080139593A1 (en) | 2008-06-12 |
US20170136016A1 (en) | 2017-05-18 |
AU2007333115B2 (en) | 2013-01-10 |
PT2101777E (pt) | 2015-09-18 |
HK1218393A1 (zh) | 2017-02-17 |
PL2101777T3 (pl) | 2015-10-30 |
AU2007333115A1 (en) | 2008-06-19 |
US20140296244A1 (en) | 2014-10-02 |
US9504685B2 (en) | 2016-11-29 |
EP2101777B1 (en) | 2015-05-20 |
JP2010512414A (ja) | 2010-04-22 |
US20110245253A1 (en) | 2011-10-06 |
CA2669536C (en) | 2016-05-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9993475B2 (en) | Method for treating a pulmonary hypertension condition | |
US20130225595A1 (en) | Method for treating pulmonary arterial hypertension in a patient not having idiopathic pulmonary fibrosis | |
US20210267951A1 (en) | Combination therapy for pulmonary hypertension | |
US20140030356A1 (en) | Method for treating a pulmonary hypertension condition without companion diagnosis | |
US20210338642A1 (en) | Compositions and methods for the treatment or prevention of pulmonary hypertension | |
WO2010062640A1 (en) | Methods for treating idiopathic pulmonary fibrosis and associated complications | |
RU2780758C2 (ru) | Комбинированная терапия легочной гипертензии |